Insurers must disclose new rates and justify increases that exceed certain thresholds
WASHINGTON-Government leaders are set to block double-digit premium hikes, forcing insurers to contend with rising costs and flat revenues. Under the Patient Protection and Affordable Care Act (PPACA), insurers must disclose new rates and justify increases that exceed certain thresholds.
Other California insurers are seeking higher premiums, too. Anthem Blue Cross is seeking a 9.8% average increase-just below the 10% threshold considered "unreasonable" in new regulations proposed late last year by the Department of Health and Human Services (HHS). Following the outrage last year over Anthem's rates, the company appears anxious to keep premium changes out of the spotlight.
State insurance regulators-not the federal government-retain authority for rejecting rates deemed unreasonable, but public disclosure of rate review information, according to HHS Secretary Kathleen Sebelius, will "rein in the kind of excessive and unreasonable rate increases that have made insurance unaffordable for so many families."
Rhode Island Insurance Commissioner Chris Koller agrees that insurance rate review will remain "essentially a state-based activity," and that the new program will provide "a backstop behind states" trying to tackle insurance rate hikes. A main benefit of the program, according to Koller, is that it offers a system for insurance commissioners to examine and question the assumptions underlying how a rate will affect enrollment demographics and other calculations used by insurers to set rates.
Karen Ignagni, president of America's Health Insurance Plans (AHIP), agrees that states are best suited to review premiums because of their knowledge of the local market and its affect on plan solvency.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Leadership Team at The Cigna Group Revamps in Efforts to Drive Growth, Enhance Customer Focus
March 13th 2025David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More